Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1].
CAS Number:
[2135632-29-8]
Target:
Virus Protease
* VAT and and shipping costs not included. Errors and price changes excepted
